NVS vs OMER
NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases. OMER: A clinical-stage biotech company commercializing complement-pathway inhibitors for rare hematologic and immune diseases, with FDA-approved YARTEMLA for stem cell transplant complications and a $240M asset sale of its lead MASP-3 program to Novo Nordisk.
Side-by-side fundamentals
| Metric | NVS | OMER | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $153.08 | $9.84 | |
| Market cap as of 2026-07-23 | $229.2B | $703M | |
| P/E as of 2026-07-23 | 22.11 | 8.16 | OMER lower |
| PEG as of 2026-07-23 | 3.66 | n/a | |
| Net margin as of 2026-07-23 | +22.5% | +566.7% | OMER higher |
| Gross margin as of 2026-07-23 | +75.0% | +94.1% | OMER higher |
| Operating margin as of 2026-07-23 | +29.9% | -176.1% | NVS higher |
| ROE as of 2026-07-23 | +29.9% | +107.5% | OMER higher |
| ROA as of 2026-07-23 | +11.1% | +34.5% | OMER higher |
| Debt / equity as of 2026-07-23 | 1.18 | 21.55 | NVS lower |
| Revenue growth (YoY) as of 2026-07-23 | +3.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | n/a | +4.4% | |
| Dividend yield as of 2026-07-23 | +3.0% | n/a | |
| Beta as of 2026-07-23 | 1.17 | 2.59 | |
| 1-year return as of 2026-07-22 close | +35.8% | +163.1% | OMER higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.